- FoI Number
- 2024-127
- Subject
- Drugs
- Date Received
- 24/05/2024
- Request and Response
-
- How many patients has your Health Board treated in the past 6 months (for any disease) with the following drugs?
Drug Name
Patient Number
Aubagio (teriflunomide)
0
Avonex (interferon beta-1a)
0
Betaferon (interferon beta-1b)
<5
Brabio (glatiramer acetate)
<5
Copaxone (glatiramer acetate)
0
Extavia (beta interferon-1b)
0
Gilenya (fingolimod)
<5
Kesimpta (ofatumumab)
0
Lemtrada (alemtuzumab)
0
Mavenclad (cladribine)
0
Mayzent (siponimod)
0
Ocrevus (ocrelizumab)
0
Plegridy (peginterferon beta-1a)
<5
Ponvory (ponesimod)
0
Rebif (beta interferon-1a)
<5
Tecfidera (dimethyl fumarate)
18
Tysabri (natalizumab)
0
Tysabri (natalizumab) Pre-filled syringes only
0
Vumerity (diroximel fumarate)
0
Zeposia (ozanimod)
0
- How many patients has your Board treated with Rituximab for MS (Multiple Sclerosis) in the past six months?
<5
- How many patients within your Board have a diagnosis of MS (Multiple Sclerosis)?
97
- Of the patients with a diagnosis of Multiple Sclerosis, how many patients have a diagnosis of:
Condition
Patient Number
RRMS – Relapse Remitting Multiple Sclerosis
17
PPMS – Primary Progressive Multiple Sclerosis
<5
SPMS – Secondary Progressive Multiple Sclerosis
<5
Where we have given <5 answers, this is because NHS Shetland considers that providing more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.
